Gradients Contact Us

A mechanistic science of human flourishing

Designing the next generation of therapeutics for well-being enhancement

AI is radically accelerating all parts of the drug development pipeline, from discovery to experimental validation. What used to take a decade and a billion dollars is becoming faster and cheaper, and soon enough by orders of magnitude. We are on a mission to leverage breakthroughs in AI for developing better therapeutics for alleviating pain and improving well-being.

Nearly every compound that reliably enhances well-being was discovered before 1990. The chemical space is all but uncharted. The first drug to sustainably raise the hedonic baseline of humans will be the most important medicine ever made.

Team

Curran Jansens

Curran Jansens

Co-Founder & CEO

Max Novendstern

Max Novendstern

Co-Founder & Chairman

David Pearce

David Pearce

Advisor

Michael Johnson

Michael Johnson

Advisor

Kristian Rönn

Kristian Rönn

Advisor

The next generation of well-being therapeutics won't discover themselves.